ESMO Exclusive Interview | Professor Huiyan Luo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors
Editor's Note: The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into…